title: A new era in the treatment of cystic fibrosis.
authors.affiliation: Newcastle Adult Cystic Fibrosis Centre, Royal Victoria Infirmary, Newcastle-upon-Tyne, UK.
authors.forename: Matthew A
authors.initials: MA
authors.lastname: Lane
authors.forename: Simon J
authors.initials: SJ
authors.lastname: Doe
mesh_terms: D000627:Aminophenols / Q000627:therapeutic use; D000631:Aminopyridines / Q000627:therapeutic use; D052117:Benzodioxoles / Q000627:therapeutic use; D003550:Cystic Fibrosis / Q000235:genetics* / Q000628:therapy*; D019005:Cystic Fibrosis Transmembrane Conductance Regulator / Q000235:genetics*; D015316:Genetic Therapy; D006801:Humans; D058990:Molecular Targeted Therapy; D009154:Mutation; D010069:Oxadiazoles / Q000627:therapeutic use; D015363:Quinolones / Q000627:therapeutic use
chemical_list: D000627:Aminophenols; D000631:Aminopyridines; D052117:Benzodioxoles; C505032:CFTR protein, human; D010069:Oxadiazoles; D015363:Quinolones; D019005:Cystic Fibrosis Transmembrane Conductance Regulator; C545203:ivacaftor; C569105:lumacaftor; C515878:ataluren
keywords: Ataluren; cystic fibrosis; gene therapy; ivacaftor; lumacaftor ▪